Verastem’s (VSTM) “Buy” Rating Reiterated at BTIG Research

Posted by Brenda Bartman on Oct 7th, 2026

Verastem (NASDAQ:VSTM – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at BTIG Research in a research report issued to clients and investors on Monday, MarketBeat.com reports. They currently have a $18.00 price target on the biopharmaceutical company’s stock. BTIG Research’s price objective would indicate a potential upside of 118.98% from the company’s previous close.

Several other analysts also recently weighed in on the company. Jefferies Financial Group cut their target price on Verastem from $15.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, June 23rd. Wall Street Zen raised Verastem from a “sell” rating to a “hold” rating in a research report on Sunday, September 27th. Cantor Fitzgerald restated an “overweight” rating on shares of Verastem in a research note on Monday, September 28th. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Verastem in a report on Monday. Finally, Guggenheim set a $12.00 price target on Verastem and gave the company a “buy” rating in a research note on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Verastem presently has a consensus rating of “Moderate Buy” and a consensus target price of $13.83.

Read Our Latest Stock Analysis on Verastem

Verastem Trading Up 6.1%

NASDAQ VSTM traded up $0.47 during mid-day trading on Monday, reaching $8.22. 1,634,957 shares of the stock were exchanged, compared to its average volume of 2,238,944. The business’s fifty day simple moving average is $7.28 and its 200 day simple moving average is $5.79. The company has a debt-to-equity ratio of 1.48, a quick ratio of 2.22 and a current ratio of 2.25. Verastem has a 1-year low of $3.43 and a 1-year high of $10.82. The stock has a market capitalization of $744.43 million, a PE ratio of -3.09 and a beta of 0.39.

Verastem (NASDAQ:VSTM – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.08. The company had revenue of $40.08 million during the quarter, compared to analyst estimates of $22.88 million. Verastem had a negative return on equity of 467.49% and a negative net margin of 231.59%. On average, research analysts anticipate that Verastem will post -1.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Verastem

In other Verastem news, CEO Dan Paterson sold 44,121 shares of the business’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $8.00, for a total value of $352,968.00. Following the completion of the sale, the chief executive officer owned 652,712 shares of the company’s stock, valued at $5,221,696. The trade was a 6.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 48,044 shares of company stock worth $381,484 over the last three months. 1.94% of the stock is currently owned by company insiders.

Institutional Trading of Verastem

Institutional investors and hedge funds have recently modified their holdings of the business. Royal Bank of Canada grew its holdings in shares of Verastem by 15.3% during the first quarter. Royal Bank of Canada now owns 110,729 shares of the biopharmaceutical company’s stock worth $587,000 after purchasing an additional 14,683 shares during the last quarter. Seven Fleet Capital Management LP bought a new stake in shares of Verastem during the fourth quarter valued at approximately $117,000. Bank of New York Mellon Corp raised its position in shares of Verastem by 31.8% during the first quarter. Bank of New York Mellon Corp now owns 161,707 shares of the biopharmaceutical company’s stock worth $857,000 after purchasing an additional 39,018 shares during the period. Hsbc Holdings PLC bought a new position in shares of Verastem in the 1st quarter worth $210,000. Finally, ADAR1 Capital Management LLC acquired a new stake in Verastem in the 1st quarter valued at $377,000. 88.37% of the stock is currently owned by institutional investors.

About Verastem

(Get Free Report)

Verastem Oncology (NASDAQ:VSTM) is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancers driven by abnormalities in the RAS/MAPK signaling pathway. The company’s research is aimed at addressing cancers with limited treatment options, including ovarian cancer and other solid tumors.

Verastem’s lead product, avutometinib, is a treatment targeting the RAF/MEK signaling pathway and is marketed in the United States under the brand name Avmapki for certain patients with recurrent low-grade serous ovarian cancer.

Analyst Recommendations for Verastem (NASDAQ:VSTM)

Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.